業績

2023年

新規抗腫瘍性化合物の開発

1. クルクミンアナログGO-Y030はHSP70/HSP40を介して癌幹細胞を死滅させる。
   A curcumin analogue GO-Y030 depletes cancer stem cells by inhibiting the interaction between the HSP70/HSP40 complex and its substrates
   Maya Suzuki, Yohei Yamamoto, Aki Nishijima-Matsunobu, Yohei Kawasaki, Hiroyuki Shibata, Yasufumi Omori. FEBS Open Bio. Vol. 13, pp 434-446, 2023.
2. クルクミンアナログ（デケットミン）と代謝制御剤2-デオキシ-グルコースによる制御性T細胞の制御
   Pyrolyzed deketene curcumin controls regulatory T cell generation and gastric cancer metabolism cooperate with 2-deoxy-d-glucose
   Takashi MaruYama, Hirofumi Miyazaki, Yun-Ji Lim, Jian Gu,　Masaki Ishikawa, Taichi Yoshida, WanJun Chen, Yuji Owada, Hiroyuki Shibata. Front Immunol. 2023; 14: 1049713.

臨床研究

1. 胚細胞性変異MSH2 c.1808A > T (Asp603Val)を有する胃癌のリンパ節転移はペムブロリズマブに応答した。
   Lymph-node metastasis from gastric adenocarcinoma in a patient bearing a germ line missense variant MSH2 c.1808A > T (Asp603Val) responds to the immune checkpoint inhibitor pembrolizumab
   Miki Kiyomiya, Koji Fukuda, Kazuhiro Shimazu, Taichi Yoshida, Daiki Taguchi, Hanae Shinozaki, Hiroshi Nanjyo, Hiroyuki Shibata. Japanese Journal of Clinical Oncology, Volume 53, March 2023, pp 270–274,
2. 日本におけるがんゲノム診断による臨床診断（後方視的観察研究）
   Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study
   Hidekazu Shirota, Keigo Komine, Masanobu Takahashi, Shin Takahashi, Eisaku Miyauchi, Hidetaka Niizuma, Hiroshi Tada, Muneaki Shimada, Tetsuya Niihori, Yoko Aoki, Ikuko Sugiyama, Maako Kawamura, Jun Yasuda, Shuhei Suzuki, Takeshi Iwaya, Motonobu Saito, Tsuyoshi Saito, Hiroyuki Shibata, Toru Furukawa, Chikashi Ishioka. Cancer medicine, Vol. 12, pp. 6170-6181, 2023.
3. リンチ症候群患者に発生した肺動脈肉腫に対する免疫チェックポイント阻害剤の効果
   Pulmonary Artery Intimal Sarcoma in a Patient with Lynch Syndrome: Response to an Immune Checkpoint Inhibitor
   Mounai Y, Yoshida T, Ito S, Fukuda K, Shimazu K, Taguchi D, Shinozaki H, Takagi D, Imai K, Yamamoto H, Minamiya Y, Nanjyo H, Shibata H. Case Rep Oncol 2023;16:21–29.